Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
JMIR Cardio|June 1, 2021
A Virtual Cardiovascular Care Program for Prevention of Heart Failure Readmissions in a Skilled Nursing Facility Population: Retrospective AnalysisDaniel M Friedman, Jana M Goldberg, Rebecca L Molinsky, et al.
European Journal of Heart Failure|July 31, 2020
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosisHannah Rosenblum, Ahmad Masri, David L Narotsky, et al.
European Heart Journal|October 12, 2017
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacementAdam Castaño, David L Narotsky, Nadira Hamid, et al.
European Journal of Heart Failure|March 2, 2026
Impact of acoramidis on clinical stability in transthyretin amyloid cardiomyopathy: Observations from ATTRibute-CMFrancesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, et al.
Circulation. Heart Failure|July 2, 2026
Effects of Acoramidis on Kidney Function in Transthyretin Amyloid CardiomyopathyJeffrey M Testani, Daniel P Judge, Barry A Borlaug, et al.
Journal of the American College of Cardiology|March 12, 2025
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyDaniel P Judge, Kevin M Alexander, Francesco Cappelli, et al.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
Journal of the American College of Cardiology|October 27, 2025
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CMAhmad Masri, Daniel P Judge, Frederick L Ruberg, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
Pageof 4